The performance of companies tied to the drug's past presents a challenging investment scenario . While the initial boom generated substantial profits , generic alternatives have significantly impacted revenue. Investing Pharma in associated pharmaceutical companies now requires a discerning assessment of proprietary rights , evolving patient shift